Study of Inupadenant (EOS100850) with Chemotherapy As Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
Launched by ITEOS THERAPEUTICS · May 31, 2022
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment option for patients with advanced non-small cell lung cancer (NSCLC) that has not responded to previous treatments. The researchers want to find the best dose of a drug called inupadenant when it is combined with two standard chemotherapy drugs, carboplatin and pemetrexed. They will then compare how well this combination works and how safe it is compared to the standard chemotherapy treatments alone.
To participate in this trial, patients need to have a confirmed diagnosis of metastatic (stage IV) or locally advanced (stage III) nonsquamous NSCLC. They should have measurable cancer and have previously been treated with an anti-PD(L)1 therapy for at least 12 weeks. Eligible participants can be of any age between 65 and 74, and both men and women can join. Once enrolled, participants will receive the new treatment and be closely monitored for any side effects and how well the treatment is working. It’s important to note that patients with certain health conditions or those who are pregnant or breastfeeding cannot participate in this trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Confirmed diagnosis of metastatic (Stage IV) or locally advanced, unresectable (Stage III) NSCLC of nonsquamous pathology
- • Measurable disease as defined by RECIST v1.1
- • PD-L1 expression status available at or after the time of diagnosis. All levels of expression are eligible.
- • Existing biopsy taken within 4 years prior to entering trial or provide fresh biopsy where safe and feasible
- • At least 12 weeks of treatment with only 1 anti-PD-(L)1 agent (mono or with IO combo) in the metastatic setting, OR at least 12 weeks of anti-PD-(L)1 agent (mono or with IO combo) following CRT in the unresectable, Stage III setting
- • ECOG performance status of 0 to 1.
- Exclusion Criteria:
- • Symptomatic central nervous system (CNS) metastases or leptomeningeal disease.
- • EGFR, ALK, or ROS1 mutation.
- • Autoimmune disease requiring systemic treatment or immunodeficiency requiring concurrent use of systemic immunosuppressants or corticosteroids
- • Hepatitis B or C infection unless adequately treated with no detectable viral load; Human immunodeficiency virus (HIV) unless well-controlled disease on therapy.
- • History of life-threatening toxicity related to prior immune therapy
- • Uncontrolled or significant cardiovascular disease
- • Pregnant or breast-feeding
- • Lack of agreement to use highly effective method of contraception during treatment and for 6 months after the last administration of chemotherapy
About Iteos Therapeutics
Iteos Therapeutics is a biopharmaceutical company dedicated to advancing innovative therapies for cancer treatment through the development of immune-oncology approaches. With a focus on harnessing the body’s immune system to combat tumors, Iteos is committed to discovering and delivering transformative therapies that improve patient outcomes. The company leverages cutting-edge science and a robust pipeline of drug candidates, aimed at addressing unmet medical needs in oncology. Iteos Therapeutics is driven by a team of experienced professionals and a collaborative ethos, aiming to lead the next generation of cancer care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tampa, Florida, United States
Lyon, , France
Lausanne, , Switzerland
Tampa, Florida, United States
Orange City, Florida, United States
Dijon, , France
Fayetteville, Arkansas, United States
Alicante, , Spain
Badajoz, , Spain
Lugo, , Spain
Milano, , Italy
Santander, , Spain
Barcelona, , Spain
Sutton, , United Kingdom
Valencia, , Spain
Nantes, , France
Chemnitz, , Germany
Brescia, , Italy
A Coruña, , Spain
Heidelberg, , Germany
Gettysburg, Pennsylvania, United States
Mons, , Belgium
Avellino, , Italy
Lucca, , Italy
Saint Mandé, , France
Dijon, , France
Roeselare, , Belgium
Madrid, , Spain
Namur, , Belgium
Hasselt, , Belgium
Mons, , Belgium
Whittier, California, United States
Brampton, Ontario, Canada
Castellón De La Plana, , Spain
Warszawa, Mazowieckie, Poland
Florham Park, New Jersey, United States
Bordeaux, , France
Gent, , Belgium
Palma De Mallorca, Illes Balears, Spain
Créteil, , France
Bordeaux, , France
Namur, , Belgium
Tyler, Texas, United States
Omaha, Nebraska, United States
Palma De Mallorca, Illes Balears, Spain
Zürich, , Switzerland
Fayetteville, North Carolina, United States
Mechelen, , Belgium
Canton, Ohio, United States
Omaha, Nebraska, United States
Manresa, , Spain
Fayetteville, North Carolina, United States
Krakow, , Poland
Poznan, , Poland
Pamplona, , Spain
Caen, , France
łódź, , Poland
Olomouc, , Czechia
Marseille, , France
Oświęcim, , Poland
Piła, , Poland
Ourense, , Spain
Praha, , Czechia
Peschiera Del Garda, , Italy
Olsztyn, Warminsko Mazurskie, Poland
Villars Sur Glâne, , Switzerland
Milan, , Italy
Rozzano, , Italy
Barcelona, , Spain
Zürich, , Switzerland
Mechelen, Antwerp, Belgium
Edmonton, Alberta, Canada
Praha 3, , Czechia
Bordeaux, , France
Marseille, , France
Saint Mandé, , France
Giessen, Hessen, Germany
Essen, , Germany
Köln, , Germany
Lowenstein, , Germany
Orbassano, , Italy
Poznan, Wielkopolskie, Poland
Badajoz, , Spain
Coruña, , Spain
Villars Sur Glâne, , Switzerland
Patients applied
Trial Officials
Iteos Clinical Trials
Study Director
iTeos Belgium SA
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials